Hasegawa K, Shimada M, Takeuchi S, Fujiwara H, et al. A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense
paclitaxel in front-line treatment of suboptimal residual ovarian cancer. Br J Cancer 2020 Jan 31. pii: 10.1038/s41416-020-0734.
PMID: 32001833